Kapil N. Bhalla, MD, chief of personalized cancer medicine at the University of Kansas Cancer Center in Kansas City, describes the findings from an in vitro study that examined treatment with histone deacetylase (HDAC) inhibitors in triple-negative breast cancer (TNBC) cells.
To view more coverage from SABCS, visit [ Ссылка ]
![](https://s2.save4k.ru/pic/xfoxvgj6r7c/mqdefault.jpg)